Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
Authors:
Top Cited Papers
Open Access
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)European Journal of Heart Failure, 2020
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEFJACC, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2019
- Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF TrialCirculation, 2019
- Titration of Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2018
- Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failureJACC, 2004
- Semiparametric Regression for the Mean and Rate Functions of Recurrent EventsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2000